GDF-8 Differentiation of Pluripotent Stem Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for differentiating pluripotent stem cells into definitive endoderm lineage cells are limited by the complexity and low yield of activin A isolation, which hinders the efficient production of insulin-producing cells for Type I diabetes treatment.

Innovation Solution

Culturing pluripotent stem cells in a medium containing a sufficient amount of GDF-8, potentially with an aniline-pyridinotriazine compound, to induce differentiation into cells expressing markers characteristic of the definitive endoderm lineage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If activin A is used to differentiate pluripotent stem cells into definitive endoderm lineage cells, then differentiation can be achieved, but the process is limited by the complexity and low yield of activin A isolation

Engineering Contradiction:

Improvedifferentiation effectivenessVSAvoidactivin A isolation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential functional property of activin A (TGF-beta superfamily signaling capability) and replaces the complex natural protein with a simplified small molecule compound that can be easily isolated and administered, eliminating the complexity of protein purification while maintaining the desired biological effect

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent creates a simplified copy or analog of activin A's function using small molecule compounds that mimic the TGF-beta signaling pathway activation without requiring the complex structure of the natural protein, thereby achieving the same differentiation effect with much simpler isolation and production

Inventive Principle:

Principle #26Copying

2Reliability

If activin A is used to differentiate pluripotent stem cells, then definitive endoderm lineage cells can be produced, but the yield is low

Engineering Contradiction:

Improvedifferentiation effectivenessVSAvoidyield of insulin-producing cells

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the chemical parameters from complex protein-based activin A to simple small molecule compounds, which enables higher concentration stability, easier dosing control, and improved scalability, thereby increasing the productivity and yield of insulin-producing cells while maintaining differentiation effectiveness

Inventive Principle:

Principle #35Parameter changes

3Reliability

If complex methods are used to isolate activin A, then differentiation can proceed, but the process becomes inefficient for producing insulin-producing cells

Engineering Contradiction:

Improvedifferentiation capabilityVSAvoidproduction efficiency

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent replaces the expensive, difficult-to-isolate activin A protein with inexpensive small molecule compounds that are stable, easy to manufacture, and can be administered in simple formulations, dramatically improving ease of manufacture and production efficiency while maintaining the ability to differentiate stem cells into insulin-producing cells

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS10351820B2Methods for making definitive endoderm using at least GDF-8

Publication Date: 2019.07.16 JANSSEN BIOTECH INC

AI summary

The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.